4M Therapeutics Inc. has been awarded a $120,000 grant from SynGAP Research Fund (SRF) to evaluate central nervous system (CNS) effects of novel glycogen synthase kinase 3 β (GSK-3β) inhibitors 4MT-2001 and 4MT-1060.